The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | MRD and disease eradication in myeloma
Jesús San Miguel
• 5 Oct 2018
We spoke to Jesús San Miguel, MD, PhD, of the University of Navarra, Pamplona, Spain, to discuss the importance of measurable residual disease (MRD) in the eradication of multiple myeloma (MM). This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
